Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Astellas Pharma Inc (OP: ALPMY ) 9.570 -0.060 (-0.62%) Streaming Delayed Price Updated: 3:10 PM EDT, Apr 30, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 220,436 Open 9.500 Bid (Size) N/A (0) Ask (Size) N/A (0) Prev. Close 9.630 Today's Range 9.500 - 9.670 52wk Range 9.150 - 16.53 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential February 22, 2024 MAIA Biotechnology, a biotechnology company developing innovative cancer treatments, has seen its stock drift downwards for the past months. Via Talk Markets Week In Review: $1.7 Billion Collaboration Between Elpiscience And Astellas Is Final 2023 Deal December 31, 2023 Shanghai’s Elpiscience Biopharma has formed a $1.7 billion collaboration with Japan’s Astellas Pharma to develop a novel bispecific macrophage engager, ES019, along with an unspecified program.... Via Talk Markets Performance YTD -19.10% -19.10% 1 Month -11.14% -11.14% 3 Month -17.50% -17.50% 6 Month -23.81% -23.81% 1 Year -37.29% -37.29% More News Read More Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024 December 29, 2023 Via Benzinga How This New Merck Regimen Could 'Rewrite Textbooks' In Cancer Treatment — And Bolster 4 Stocks October 22, 2023 Via Investor's Business Daily Merck's Best Selling Cancer Drug Meets One Goal In Late-Stage Bladder Cancer Study October 05, 2023 Via Benzinga Here Are the 3 George Soros Stocks Most Likely to Turn $200,000 Into $1 Million Over the Next 20 Years September 24, 2023 Via The Motley Fool Why Is Seagen Stock Trading Higher Today? September 22, 2023 Via Benzinga Seagen Pops After Scoring A 'Must-Win' For Its $43 Billion Takeover By Pfizer September 22, 2023 Via Investor's Business Daily What's Going On With Neurology Focused Taysha Gene Therapies Stock Today? September 20, 2023 Via Benzinga How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks? September 01, 2023 Via MarketBeat Topics Economy Exposures Interest Rates Here's Why Embattled Apellis Stock, A Former Highflier, Just Took Another Hit To The Chin August 07, 2023 Via Investor's Business Daily From AI to Obesity Drugs - Global Pharma Has $700B For M&A and Investments: Goldman Sachs July 07, 2023 Via Benzinga Week In Review: Cullgen Signs $1.9 Billion Protein Degrader Deal With Astellas June 17, 2023 Via Talk Markets Astellas Pharma Licenses Promising Gene Therapy KT430 from Kate Therapeutics Amidst Clinical Hurdles June 08, 2023 Via Benzinga The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree June 02, 2023 Via Investor's Business Daily Why Shares of Annexon Are Plummeting Thursday May 25, 2023 Via The Motley Fool Google Launches Tools To Detect Fake Images, Apple May Encounter Delays In iPhone 15 Production, Shake Shack Sees Activist Investor Proxy Fight: Today's Top Stories May 15, 2023 Via Benzinga Astellas' Menopause Drug Sores FDA Approval, After Regulatory Setback May 15, 2023 Via Benzinga Why Apellis Pharmaceuticals, TG Therapeutics, and Viking Therapeutics Were on the Move Today May 01, 2023 Via The Motley Fool Pfizer, Astellas' Xtandi Combo Therapy Cuts Risk Of Metastasis, Death In Prostate Cancer By 58% May 01, 2023 Via Benzinga Biotech Buying Bonanza: Iveric Bio Snags $5.9 Billion Deal From Astellas Pharma May 01, 2023 Via Investor's Business Daily First Republic Folds Amid Banking Crisis, Elon Musk Expects Starship To Make Orbit On Next Launch, DOJ Probes Mastercard Over Anti-Competitive Debit-Card Practices: Today's Top Stories May 01, 2023 Via Benzinga Nasdaq, S&P 500 Futures On Edge Over First Republic Failure, Tech Earnings: Analyst Pins Hopes On Fed's Next Move May 01, 2023 Via Benzinga Astellas Pharma Acquires Iveric Bio For $5.9B To Focus On 'Blindness & Regeneration' May 01, 2023 Via Benzinga FDA Approves Merck's Keytruda Combined With Seagen/Astellas's Padcev For Advanced Urothelial Cancer April 04, 2023 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
